AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1298332
Drug: Inhaled Bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Bradykinin (8 mg/mL)
Trial: 31666084
Drug: umeclidinium/vilanterol 62.5/25
RxNorm normalized name: umeclidinium/vilanterol 62.5/25 MCG/INHAL Dry Powder Inhaler, 7 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umeclidinium/vilanterol 62.5/25 μg once-daily
Trial: 31666084
Drug: umeclidinium 62.5
RxNorm normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umeclidinium 62.5 μg once-daily
Trial: 31666084
Drug: salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 50 μg twice-daily
Trial: 25896890
Drug: Serum bicarbonate
RxNorm normalized name: BICARBONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum bicarbonate >26 mmol/L
Trial: 25896890
Drug: Serum bicarbonate
RxNorm normalized name: BICARBONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum bicarbonate <22 mmol/L
Trial: 25896890
Drug: Serum bicarbonate
RxNorm normalized name: BICARBONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum bicarbonate 22 to 26 mmol/L
Trial: 19843669
Drug: 1C diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1C diet (single dose of cruciferous vegetables)
Trial: 19843669
Drug: 2C diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2C diet (double dose of cruciferous vegetables)
Trial: 19843669
Drug: 1C+A diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1C+A diet (single dose of cruciferous and apiaceous vegetables)
Trial: 16915511
Drug: Polyglactin/polypropylene compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyglactin/polypropylene compound mesh (group C)
Trial: 11734734
Drug: Intranasal trivalent
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal trivalent influenza vaccine (CAIV) - 3 lots (A/Shenzhen/227/95 (H1N1), A/Wuhan/359/95 (H3N2), B/Harbin/7/94-like)
Trial: 16551139
Drug: Self-administered behavioral
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered behavioral family intervention
Trial: 16551139
Drug: Self-administered behavioral
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered behavioral family intervention plus brief therapist telephone assistance
Trial: 12105157
Drug: Aspirin, heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, heparin, and meloxicam
Trial: 10202220
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (50/250 microg bid) via a single Diskus inhaler (combination)
Trial: 10202220
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg bid via one Diskus inhaler and fluticasone propionate 250 microg bid via another (concurrent)
Trial: 7008938
Drug: Weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly regimen of ICRF-159
Trial: 31914437
Drug: Aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2 mg intravitreal injections every 4 weeks, adjusted based on CSMT changes
Trial: 23294776
Drug: Dulaglutide (dula,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (dula, LY2189265) - a once-weekly glucagon-like peptide-1 analog
Trial: 16044027
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg twice daily for 6 months)
Trial: 16044027
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg twice daily for 1 month)
Trial: 7771102
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with non-steroidal anti-inflammatory drugs (2/3)
Trial: 7771102
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with morphine (0/1)
Trial: 7771102
Drug: Placebo iontophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo iontophoresis (lidocaine, procaine, flufenamic acid, diclofenac, Mobilat, vinca-alkaloids, dexamethasone-lidocaine, morphine, fluoride)
Trial: 7771102
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration (procaine, benzocaine-salicylamide, flufenamic acid)
Trial: 7771102
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration without current (procaine, flufenamic acid)
Trial: 2178489
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and fentanyl (continuous infusion)
Trial: 2178489
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and fentanyl (intermittent bolus injections)
Trial: 2178489
Drug: Diazepam and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam and fentanyl (continuous infusion)
Trial: 2178489
Drug: Diazepam and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam and fentanyl (intermittent bolus injections)
Trial: 6777812
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (250 mg per week)
Trial: 6777812
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (12.5 mg per week)
Trial: 26951309
Drug: Apitolisib 40
RxNorm normalized name: Apitolisib
DrugBank: Apitolisib (DB12180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apitolisib 40 mg once per day
Trial: 26951309
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg once per day
Trial: 25027140
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg/d)
Trial: 22236497
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg/day for 6 weeks)
Trial: 19151659
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 x 1 g daily for 6 months
Trial: 19151659
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (fluocortolone and topical prednisolone acetate)
Trial: 6209832
Drug: Hemodilution therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution therapy (venesection of 250‐650 ml during the first 2 days and low‐molecular weight dextran administration)
Trial: 29439736
Drug: Formula A
RxNorm normalized name: ACD-Solution Formula A
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formula A (1.2 g/100 mL)
Trial: 29439736
Drug: Formula B
RxNorm normalized name: Formula B
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula B (1.7 g/100 mL)
Trial: 10647066
Drug: Test diet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test diet with high soy protein and soluble fiber (12 +/- 2 g/d soy protein)
Trial: 8346486
Drug: WEB 2086
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WEB 2086 (100 mg three times a day)
Trial: 3732901
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N hydrochloric acid infusion
Trial: 3732901
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N hydrochloric acid infusion in patients without duodenal ulcer
Trial: 21944168
Drug: High-intensity weight-lifting
RxNorm normalized name: chitosan high molecular weight (400-800 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity weight-lifting exercise and targeted multidisciplinary treatment
Trial: 12055582
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral supplementation for 5 days with 1 L/day of a formula enriched with arginine, omega-3 fatty acids, and RNA (n = 102)
Trial: 12055582
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral supplementation plus postoperative jejunal infusion with the same enriched formula (n = 101)
Trial: 10606379
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% diclofenac in lecithin organogel
Trial: 8695584
Drug: Diazepam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.3 mg/kg) administered at home 60 minutes before treatment
Trial: 8695584
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at home 60 minutes before treatment
Trial: 2064345
Drug: Tamoxifen (2x20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (2x20 mg/day)
Trial: 2064345
Drug: Tamoxifen +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen + Prednisolone (3x2.5 mg/day)
Trial: 6677080
Drug: Two-year primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-year primary prevention program consisting of drug education, 'alternatives,' and affective in-service training for teachers.
Trial: 30769293
Drug: No DHP‐PMX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No DHP‐PMX therapy
Trial: 25618970
Drug: Gushenyutai plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gushenyutai plaster plus comprehensive therapy
Trial: 25618970
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy alone
Trial: 15239288
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5‐FU + leucovorin)
Trial: 11559727
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment by surgeons treating more than 10 cases
Trial: 7750185
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment skill of pause and regress in six parts
Trial: 23135774
Drug: Tramadol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1.5 mg/kg within 0.9% saline solution)
Trial: 23135774
Drug: Levobupivacaine (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (0.25% in 0.9% saline solution)
Trial: 17174704
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) strategy (NNRTI plus NRTI; n=463)
Trial: 17174704
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI) strategy (PI plus NRTI; n=470)
Trial: 14601763
Drug: Sequential conditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential conditional probability ratio tests (SCPRTs)
Trial: 10974295
Drug: Azithromycin (3‐day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (3‐day course, oral dose of 10 mg/kg per day)
Trial: 10974295
Drug: Topical oxytetracycline/polymyxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxytetracycline/polymyxin ointment (twice a day for 2 months)
Trial: 8792795
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of usual treatment (methotrexate, penicillamine, or sulfasalazine)
Trial: 1621750
Drug: Loracarbef (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef (200 mg capsules twice a day or 15 mg/kg/day suspension)
Trial: 1621750
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK (250 mg capsules four times a day or 20 mg/kg/day suspension)
Trial: 7113952
Drug: Treadmill exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill exercise (mild) increasing daily expenditure to 110% of sedentary expenditure
Trial: 7113952
Drug: Treadmill exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill exercise (moderate) increasing daily expenditure to 125% of sedentary expenditure
Trial: 7113952
Drug: Sedentary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedentary treatment
Trial: 31475793
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rivaroxaban plus a single antiplatelet agent
Trial: 27775865
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus low-dose tacrolimus (EVR+LTac)
Trial: 23437144
Drug: 0.25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 µg calcitriol per day
Trial: 12153554
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with ursodeoxycholic acid (500 mg bid) and pravastatin (20 mg bid) for three weeks before cholecystectomy
Trial: 12153554
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with ursodeoxycholic acid and pravastatin
Trial: 9817157
Drug: Sharpened cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sharpened cut-off values and time- and treatment-specific PEFs
Trial: 9817157
Drug: Morning peak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning peak expiratory flow before any (bronchodilator) treatment
Trial: 7543891
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate (HDR) conformal boost brachytherapy with 45.6 Gy whole pelvis external irradiation and three HDR fractions of 5.5 Gy each (18 patients) or 6 Gy each (15 patients) to the prostate.
Trial: 2708231
Drug: Inhaled lipopolysaccharides
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lipopolysaccharides (LPS) from Escherichia coli 026:B6 (22.2-micrograms total dose)
Trial: 2708231
Drug: Placebo procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo procedure (diluent substituted for LPS solution)
Trial: 24833003
Drug: Liberal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal blood glucose management (BGM) (120-180 mg/dl)
Trial: 24833003
Drug: Strict blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict blood glucose management (BGM) (90-110 mg/dl)
Trial: 21771085
Drug: scGOS/lcFOS mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scGOS/lcFOS mixture (8 g/l)
Trial: 2752698
Drug: Dyazide (triamterene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyazide (triamterene 50 mg and hydrochlorothiazide 25 mg)
Trial: 331919
Drug: Cyclandelate (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (1200 mg daily) plus amitriptyline
Trial: 29553435
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts plus Zn sulphate (10 mg for children younger than 6 months; 20 mg for children aged 6 months and older)
Trial: 29553435
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts plus Zn sulphate
Trial: 30324839
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts
Trial: 27439082
Drug: Successful aging
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful aging intervention: weekly health education sessions for 6 months, then monthly.
Trial: 22791092
Drug: Intratracheal lucinactant
RxNorm normalized name: lucinactant Intratracheal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal lucinactant (175 mg/kg)
Trial: 20976802
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using hexylaminolevulinate (HAL) and methylaminolevulinate (MAL)
Trial: 12060470
Drug: Graphic analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graphic analysis using a* and L* values from reflectance spectrometer measurements.
Trial: 2192454
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 500 mg dimethylpolysiloxane (DPS)/24 hours
Trial: 2192454
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg dimethylpolysiloxane (DPS)/12 hours
Trial: 28653424
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of anesthetic ointment (lidocaine/prilocaine‐AO)
Trial: 22185749
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.4 mg/mL applied intraoperatively for 5 minutes
Trial: 19821717
Drug: Haishengsu (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haishengsu (2.4 mg, intravenously for 15 days)
Trial: 9309996
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at rest
Trial: 9309996
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) during exercise
Trial: 24127448
Drug: Vintafolide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vintafolide (2.5 mg IV three times per week during weeks 1 and 3) plus PLD (50 mg/m(2) IV once every 28 days)
Trial: 24127448
Drug: PLD alone
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD alone (50 mg/m(2) IV once every 28 days)
Trial: 18182447
Drug: GH 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 0.8 mg/d
Trial: 18182447
Drug: GH 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1.6 mg/d
Trial: 18182447
Drug: GH and
RxNorm normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH and DHEA (combination treatment)
Trial: 16687344
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment (LLT) after CABG (group 1, n = 102, 49% male)
Trial: 16687344
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering treatment (group 2, n = 107, 42% male)
Trial: 11024215
Drug: ACEI (Angiotensin-Converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (Angiotensin-Converting Enzyme Inhibitor)
Trial: 11024215
Drug: CCB (Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB (Calcium Channel Blocker)
Trial: 30296325
Drug: Topical bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bromfenac 0.09% (12 eyes)
Trial: 30296325
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 0.1% (12 eyes)
Trial: 26412463
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (500 µg), Folic Acid (400 µg), and Vitamin D3 (600 IU) supplementation
Trial: 19171089
Drug: Propofol controlled-infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol controlled-infusion at 1 microg/ml
Trial: 19171089
Drug: Propofol controlled-infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol controlled-infusion at 2 microg/ml
Trial: 19171089
Drug: Propofol controlled-infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol controlled-infusion at 3 microg/ml
Trial: 19171089
Drug: Propofol controlled-infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol controlled-infusion at 4 microg/ml
Trial: 19171089
Drug: Propofol controlled-infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol controlled-infusion at 5 microg/ml